Literature DB >> 8554068

Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene.

S L Primo-Parmo1, C F Bartels, B Wiersema, A F van der Spek, J W Innis, B N La Du.   

Abstract

The silent phenotype of human butyrylcholinesterase (BChE), present in most human populations in frequencies of approximately 1/100,000, is characterized by the complete absence of BChE activity or by activity <10% of the average levels of the usual phenotype. Heterogeneity in this phenotype has been well established at the phenotypic level, but only a few silent BCHE alleles have been characterized at the DNA level. Twelve silent alleles of the human butyrylcholinesterase gene (BCHE) have been identified in 17 apparently unrelated patients who were selected by their increased sensitivity to the muscle relaxant succinylcholine. All of these alleles are characterized by single nucleotide substitutions or deletions leading to distinct changes in the structure of the BChE enzyme molecule. Nine of the nucleotide substitutions result in the replacement of single amino acid residues. Three of these variants, BCHE*33C, BCHE*198G, and BCHE*201T, produce normal amounts of immunoreactive but enzymatically inactive BChE protein in the plasma. The other six amino acid substitutions, encoded by BCHE*37S, BCHE*125F, BCHE*170E, BCHE*471R, and BCHE*518L, seem to cause reduced expression of BChE protein, and their role in determining the silent phenotype was confirmed by expression in cell culture. The other four silent alleles, BCHE*271STOP, BCHE*500STOP, BCHE*FS6, and BCHE*I2E3-8G, encode BChES truncated at their C-terminus because of premature stop codons caused by nucleotide substitutions, a frame shift, or altered splicing. The large number of different silent BCHE alleles found within a relatively small number of patients shows that the heterogeneity of the silent BChE phenotype is high. The characterization of silent BChE variants will be useful in the study of the structure/function relationship for this and other closely related enzymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8554068      PMCID: PMC1914969     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  72 in total

1.  Suxamethonium in the absence of pseudocholinesterase.

Authors:  S M HART; J V MITCHELL
Journal:  Br J Anaesth       Date:  1962-03       Impact factor: 9.166

2.  Differential inhibition of human serum cholinesterase with fluoride: recognition of two new phenotypes.

Authors:  H HARRIS; M WHITTAKER
Journal:  Nature       Date:  1961-07-29       Impact factor: 49.962

3.  A new and rapid colorimetric determination of acetylcholinesterase activity.

Authors:  G L ELLMAN; K D COURTNEY; V ANDRES; R M FEATHER-STONE
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

4.  On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers.

Authors:  W KALOW; N STARON
Journal:  Can J Biochem Physiol       Date:  1957-12

5.  A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers.

Authors:  W KALOW; K GENEST
Journal:  Can J Biochem Physiol       Date:  1957-06

6.  A comparison of optical and manometric methods for the assay of human serum cholinesterase.

Authors:  W KALOW; H A LINDSAY
Journal:  Can J Biochem Physiol       Date:  1955-07

7.  A 'silent' pseudo-cholinesterase gene.

Authors:  J LIDDELL; H LEHMANN; E SILK
Journal:  Nature       Date:  1962-02-10       Impact factor: 49.962

8.  Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from trans-Caucasian Georgia and from Europe.

Authors:  G Ehrlich; D Ginzberg; Y Loewenstein; D Glick; B Kerem; S Ben-Ari; H Zakut; H Soreq
Journal:  Genomics       Date:  1994-07-15       Impact factor: 5.736

9.  Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA.

Authors:  O Jbilo; C F Bartels; A Chatonnet; J P Toutant; O Lockridge
Journal:  Toxicon       Date:  1994-11       Impact factor: 3.033

10.  Genetic basis of the silent phenotype of serum butyrylcholinesterase in three compound heterozygotes.

Authors:  M Maekawa; K Sudo; T Kanno; K Kotani; D C Dey; J Ishikawa; M Izumi; K Etoh
Journal:  Clin Chim Acta       Date:  1995-02-28       Impact factor: 3.786

View more
  15 in total

1.  Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy.

Authors:  Carmen C Garcia; Joseph G Potian; Kormakur Hognason; Baskaran Thyagarajan; Lester G Sultatos; Nizar Souayah; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-26       Impact factor: 4.310

Review 2.  Resurrection and Reactivation of Acetylcholinesterase and Butyrylcholinesterase.

Authors:  Andrew J Franjesevic; Sydney B Sillart; Jeremy M Beck; Shubham Vyas; Christopher S Callam; Christopher M Hadad
Journal:  Chemistry       Date:  2019-02-13       Impact factor: 5.236

3.  Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.

Authors:  Sadaf Munir; Rabia Habib; Sliha Awan; Nazia Bibi; Arooj Tanveer; Sajida Batool; Syed M Nurulain
Journal:  J Mol Neurosci       Date:  2019-02-01       Impact factor: 3.444

4.  Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity.

Authors:  Ivo F Panhuizen; Marc M J Snoeck; Soledad Levano; Thierry Girard
Journal:  Case Rep Med       Date:  2010-06-17

5.  Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population.

Authors:  Melih O Babaoglu; Turgay Ocal; Banu Bayar; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-01-21       Impact factor: 2.953

6.  Enhancement of Fear Extinction Memory and Resistance to Age-Related Cognitive Decline in Butyrylcholinesterase Knockout Mice and (R)-Bambuterol Treated Mice.

Authors:  Weiwei Liu; Yan Cao; Yue Lin; Keai Sinn Tan; Haishan Zhao; Haihua Guo; Wen Tan
Journal:  Biology (Basel)       Date:  2021-05-05

Review 7.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions.

Authors:  Jasmina Minic; Arnaud Chatonnet; Eric Krejci; Jordi Molgó
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Supporting precision medicine by data mining across multi-disciplines: an integrative approach for generating comprehensive linkages between single nucleotide variants (SNVs) and drug-binding sites.

Authors:  Amrita Roy Choudhury; Tiejun Cheng; Lon Phan; Stephen H Bryant; Yanli Wang
Journal:  Bioinformatics       Date:  2017-06-01       Impact factor: 6.937

10.  Butyryl-cholinesterase deficiency: A case report of delayed recovery after general anaesthesia.

Authors:  Ahmed Al-Emam
Journal:  Toxicol Rep       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.